Merck & Co., Inc. $MRK Stock: Choreo LLC Grows Stake

Choreo LLC boosted its stake in Merck & Co., Inc. (NYSE:MRK) by 2.8% in the third quarter, Holdings Channel reports. The firm owned 132,677 shares of the company’s stock after purchasing an additional 3,607 shares during the quarter. Choreo LLC’s holdings in Merck & Co., Inc. were worth $19,390,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after acquiring an additional 1,073,507 shares in the last quarter. State Street Corp raised its position in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP raised its position in Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after purchasing an additional 1,934,312 shares in the last quarter. Bank of America Corp DE lifted its stake in Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after purchasing an additional 2,919,780 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Merck & Co., Inc. by 23.8% during the first quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock worth $1,858,938,000 after purchasing an additional 2,969,856 shares during the last quarter. 76.07% of the stock is owned by institutional investors.

Merck & Co., Inc. Trading Up 3.8%

NYSE MRK opened at $146.32 on Friday. The company has a market cap of $360.99 billion, a price-to-earnings ratio of 117.05, a price-to-earnings-growth ratio of 6.49 and a beta of 0.21. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The business’s fifty day moving average is $146.89 and its 200 day moving average is $126.49.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.58 EPS. As a group, sell-side analysts expect that Merck & Co., Inc. will post 2.64 EPS for the current fiscal year.

Insider Activity

In other news, EVP David R. Maraldo sold 18,706 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the transaction, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares of the company’s stock, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by company insiders.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Beat-and-raise results supported the stock. Merck lifted its 2026 adjusted earnings outlook, helped by better performance from Keytruda—including the newer Qlex formulation—and recently launched products. The company’s sales forecast was raised to approximately $66.8 billion-$67.3 billion. MRK Q3 earnings and sales beat estimates
• Positive Sentiment: Growth from newer products is helping offset longer-term patent concerns. WINREVAIR revenue rose sharply, reaching about $694 million, while Keytruda and Qlex sales remained resilient. Investors are looking for these products to reduce Merck’s dependence on Keytruda before its expected patent-related erosion later in the decade. Merck revenue up on Keytruda and Winrevair growth
• Positive Sentiment: Oncology pipeline news improved Merck’s growth narrative. Phase 3 data showed KEYTRUDA reduced the risk of disease progression in advanced endometrial cancer, while sacituzumab tirumotecan produced positive late-stage results and received FDA priority review. These developments could expand Merck’s future cancer franchise if approvals and commercialization succeed. Merck Phase 3 endometrial cancer data and FDA review
• Neutral Sentiment: Near-term revenue quality remains mixed. Management indicated that roughly $550 million of quarterly sales benefited from customer-purchase timing, suggesting underlying growth was closer to flat. Merck also warned of generic-drug headwinds in 2027, making pipeline execution increasingly important.
• Negative Sentiment: Patent-cliff and legal risks remain overhangs. Keytruda’s eventual loss of exclusivity remains the central long-term concern, and a law firm announced an investigation into potential securities-law violations related to an October 22 disclosure. No wrongdoing has been established.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Jefferies Financial Group raised their target price on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price target for the company in a report on Wednesday, August 12th. Citigroup upped their price objective on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research report on Monday, October 12th. Argus raised their price objective on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Finally, Cantor Fitzgerald lifted their target price on Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Seventeen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $153.12.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.